allergan will train about 80,000 injectors this year.t harvard trains in all of its university every year. >> quick question on capital allocation some shareholders are clamoring for more in terms of share repurchases. you are generating about 5 billion in free cash flow. there are those that say there's plenty to be used for buy backs, given how cheap the stock is are you listening to them? >> i agree with you. the stop is inexpensive. we continue to look at buy backs. keep in mind, we bought $17 billion of stock back in the last two years, so it is not like we aren't participating in a robust way buying back stock, but remember, we have to invest for growth, and we are working hard to reduce debt to two and a half renleverage ratio >> some suggested the company break up meaningfully. at this point i think you're still pursuing sale of anti-infectives and women's health bring us up to date on that and answer those that should say you should have a more meaningful breakup. >> we did a comprehensive review with the board to find out what'

a company like allergan could benefit. people don't advertise prices. the average price of botox is x, that might be a benefit. that's all cash pay also maybe they'd get away with it. i think the super high price and maybe other drug companies which many of those i don't cover being affected the most. some of the companies that have higher cash paying businesses might turn out -- might be a win for them >> david, thank you. appreciate your time today. >> thank you. >>> after nearly a decade of struggling, is the business jet market getting ready to take off? phil lebeau live in orlando, florida, with more hi, phil. >> reporter: it is coming back no doubt about that. there's always been muted optimism that things would take off. they're still working off the inventory that was built up during the recession of 2008 and next year they expect shipments

which also reported this morning beat and raise for allergan.unders on "squawk on the street" today tune in for that for more on what's going on in drug pricing and politics. >> thank you, meg. joining us now is mike bailey, director of research at fbb capital partners mike, when you hear from trump and you just -- just the general environment we're in right now doesn't seem like a great pricing environment for pharmaceuticals. as a general rule would you say be cautious or watch where you step in this arena right now >> i don't know if i'd quite go in that direction. so, yeah as you mentioned, trump called pfizer directly and said cut your prices. guess what pfizer just beat on earnings >> they missed on revenue. they had to lower the top end of their guidance >> that's true. >> they missed on the current quarter. i mean that -- are you long pfizer or something? >> we are. it is. it's one of our top. pfizer's in good shape it's the tan minivan these days. in some ways that's a good thing. >> ooh, no it's not a good thing. that's what becky driv

thirdly come out in large numbers with these opening ceremony which is the biggest political event allergan see the us hosted in forty years and the biggest sporting events but most of the full thousand athletes with a participated in. four new tents of a night it karate roller sports sport climbing and break dancing the aim to make the olympics more relevant to the next generation and she used them to tackle issues concerning why the society such as race and gender equality i think. the point here is yes to use this for us now to be against these bees it's not just a power there with. women's and women's in general just to feel more confident. the debate is part of what's being called the limp is an action using sports tackle major issues that concern the younger generation of the next twelve days it's the school that will take center stage with the limping games have become. the new trend their al-jazeera when osiris. searsport folly thank you very much paul that's it for this news hour on al-jazeera from me for me back to one home team and don thanks for watching. responding to e.u. crit

j & j is up, allergan up. if we continue this conversation, we know it matters to all of you not just as shareholders but consumers, we told you yesterday about cvs' attempt to disrupt health care with its official merger partner, aetna, but look who's coming up from behind. a new disrupter, medley, which promises to put brick and mortar pharmacies like cvs out of business all together. before you roll your eyes, you got to hear the medley partner. he's here in a fox business exclusive. i first saw this and said wait a minute, wait a minute. how are you going to do that? how are you going to put cvs which is on every corner in my state of new jersey out of business? >> that's a great question. i think we are going to start off by figuring out one brick and mortar pharmacy in each major city and we take that one pharmacy and do all the distribution through there. we're not relying on physical storefronts which obviously cost a lot for cvs to make and run. liz: okay. since you launched about, what was it, a year

our quarterly report jon, pete and weiss are up today >>> allergan bought a lot of companies.s value there i would buy it here. >> i've been long this name for three months now they just continue to flood in i love the way it's moving and i'm not taking any profits i'm just rolling up, rolling up. >> their favorite stock in the universe of that is nike i would agree. i've liked the name for a long time unbelievable cash and growth globally >> all right that's where we begin, all good calls. up 8% since mid-july >> i'm staying -- look, the ceo went from being the best ceo to allegedly the worst. i think it's the former not the latter so management there has reasserted themselves in terms of control, steady as she goes no more big acquisitions maybe some demerging of it i think it's a quality company and health care continues to be a place i want to be >> jon, square >> love it great call >> it was lucky. because i had some stops and starts with twitter. jack's other company, his other job. this one he has been killing it. now a payroll app coming love this one. still hold it. i

allergan up 1.75%. i don't know, edward lawrence, if you are following this, it doesn't look like there's nervousness that the thumb is going to come down on big pharma because investors are still in. reporter: exactly. investors saying there is still value there. they are still making money, these huge companies. the president today announcing he's going to change the rules and allow medicare among other things to negotiate the best deal among the drug manufacturers. he says that reducing drug prices has been a major push of his administration and he calls this a revolutionary change. >> we are taking aim at the global freeloading that forces american consumers to subsidize lower prices in foreign countries through higher prices in our country. reporter: the president says that drug companies raise their prices in the u.s. in order to cover losses or reduce prices in other countries because those countries have controls related so the white house says in the hundred days after releasing their plan over

allergan sputtered and now catching a bid still ridiculously undervalued and see it going higher. >> they haven't really been able to monetize the acquisition and think there's an opportunity to get into the position. >> the president called out by name nucor in the steel space and aks as well as u.s. steel which is letter "x." i like both and bought ak steel and "x" during the show. >> interesting appreciate you bringing that to us. >> thank you, sir. >> shannon, thanks so much for being here stocks are up, dow up 200. power outag power pour -- lunch picks it up. >> we have a deal. president trump speaking about america's new trade agreement with mexico and canada how different is it from the hold one that he reviles and what does it mean for a trade war with china investors like what they're hearing. whatever it is, the bulls are in charge as we kick off the new month, the new quarter the fourth quarter of the year, is it rally on from here until the end of the year? we'll take a look, soaring tesla on news of a settlement between elon musk and s.e.c. and general electric jumping a